Clincosm LogoSign in Get a demo

FERIplaq: Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05848986
Collaborator
(none)
20
Enrollment
1
Location
22
Anticipated Duration (Months)
0.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Anaphylactic shock is the most severe expression of immediate hypersensitivity reactions. The mechanisms leading to these reactions are still poorly understood and may involve platelets, especially in the most severe forms.

The IgE ( ImmunoglobulineE)-mediated mechanism, involving the FcERI(the high-affinity receptor for the Fc region of immunoglobulin E (IgE) receptor present on the surface of mast cells and basophilic cells, is the most common mechanism. The receptors FcERI and FcERII are also described as being present on the surface of blood platelets, which would imply their activation along with the other cells involved. However, studies showing the presence of the FcERI/RII receptors on blood platelets suffer from many biases.

The main objective of the research is to study whether the FcERI/RII receptors are present and functional on the surface of blood platelets from allergic patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Flow cytometry

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Apr 1, 2025

Outcome Measures

Primary Outcome Measures

  1. Presence of functionnal FcERI/RII receptors on the surface of blood platelets from allergic patients [1 day]

    After confirmation of the allergy by a well conducted allergy workup

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Age > 18 years-old

  • With a protein/drug allergy (hymenoptera, arachide, amoxicillin)

  • Confirmed by skin tests and/or challenge test

  • With specific IgEs

Exclusion Criteria:

  • Patients who refuse to participate to this study

  • Patients unable to consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Les Hôpitaux Universitaires Strasbourg France 67091

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

  • Principal Investigator: CHARLES AMBROISE TACQUARD, MD, University Hospital, Strasbourg, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT05848986
Other Study ID Numbers:
  • 8947
First Posted:
May 8, 2023
Last Update Posted:
May 8, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 8, 2023